Polar Capital Technology Trust (416.25p and 4% of the JIC portfolio) I have this morning bought a 4% holding in the Polar Capital Technology Trust. There are a couple of longer term themes that I am backing in the JIC portfolio; biotechnology and healthcare through the Biotech Growth Trust and Worldwide Healthcare Trust and technology through Herald Investment Trust and now also, the Polar Capital Technology Trust.
The Trust’s investment objective is to achieve above average capital growth by investing in a globally diversified portfolio of technology companies which is different to the Herald Trust which is focussed more on mid and smaller cap companies and on the UK, which accounts for 65% of its assets.
As at 12th March Polar Capital Technology had a market value of £531m and net assets per share of 435.06p. The shares stand at a discount of about 4.5% to net asset value. It is currently invested around 70% in the US, 14% in Asia Pacific, 9% in Europe3% in the Middle East and the remainder in cash. The top 10 holdings account for around 37% of assets and include Apple, Google, Microsoft, Samsung, IBM, Oracle, Qualcomm, Taiwan Semiconductors, SAP and Cisco.
The Trust charges a management fee of 1% per annum and a performance fee of 15% of the amount by which the increase in the adjusted Net Asset Value per share exceeds the total return on the Dow Jones World Technology Index (total return, Sterling adjusted) multiplied by the time weighted average of the number of shares in issue during that period, subject to a high water mark. I'm not keen on performance fees as I think you get paid to do your job and should be trying your hardest whatever.
Conclusion: Buying this Trust has increased my exposure to technology companies, the USA and $US, all of which I am happy with. It is well managed and has a good performance record.
I funded the purchase by reducing the Herald Investment Trust to 4% and taking profits in the Lyxor ETF China Enterprise Fund which I have sold out of completely. (See Transactions)
"The investments and any other products mentioned in the johnsinvestmentchronicle website should not in any way be considered advice to buy or sell anything. Any information on the website is given in general terms and does not constitute personal advice to any individual. Readers are responsible for developing and applying their own strategies based on their personal circumstances and furthermore readers should obtain independent financial advice from an FSA regulated intermediary before investing money. Information or views in older blogs may become outdated and should not be relied upon unless confirmed by recent comment." "johnsinvestmentchronicle takes every care to ensure that the factual information on its website is accurate but cannot guarantee this."